Temozolomide

目录号:S1237 别名: CCRG81045, NSC 362856

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide(TMZ)是一种单功能的SN-1烷化剂,修饰DNA环上的氮原子以及环外氧基团。在生理pH值下,TMZ转化为活性产物MTIC、降解为methyldiazonium cation,后者再将甲基转移到DNA, 阻碍DNA复制启动,诱使细胞凋亡,是一种DNA损伤诱导剂。

规格 价格 库存 购买数量  
RMB 521.97 现货
RMB 574.37 现货
RMB 1411.95 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的6个实验数据:

  • C57BL/6 mice were implanted in the striatum with citrine-GL26-Cherry-HMGB1, which were stably transfected to express the YFP citrine and HMGB1 fused to red fluorescent protein cherry. Fourteen days later, they were treated with saline, Ad-TK+Ad-Flt3L, or Ad-TK+Ad-Flt3L+TMZ (temozolomide). Five days after treatment, the cellular location of cherry-HMGB1 in these cells was assessed by confocal microscopy. Arrows, tumor cells (green) with cytoplasmic HMGB1 (red).

    Clin Cancer Res 2014 20(6), 1555-65. Temozolomide purchased from Selleck.

    Talazoparib and temozolomide exhibit marked combinatorial efficacy in PDXs. A, Western blot against MGMT by near-infrared imaging in PDX models.

    Clin Cancer Res, 2017, 23(2):523-535. Temozolomide purchased from Selleck.

  • J Control Release, 2018, 269:245-257. Temozolomide purchased from Selleck.

    Viability of U87 cells(A) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs temozolomide (TMZ) and Bliss interaction index (B) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 400 μM TMZ(A) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-18.. Temozolomide purchased from Selleck.

  • Cells were plated and 12 h after plating were treated with MMF (5 µM), FTY720 (50 nM), Temozolomide (TMZ, 3 µM) or in combination as indicated for 12 h. Cell viability was assessed by live / dead assay.

    Cancer Biol Ther, 2014, 15(12):1646-57. Temozolomide purchased from Selleck.

    Establishment of TMZ-resistant (TR) GBM cell lines. a-d, Evaluation of temozolomide resistance in four glioblastoma cell lines. Cells were cultured in the presence of 5-600 μM of TMZ. A dose-dependent association between the survival rate of cells and TMZ concentration can be observed. Each group was cultured for 24 h in the presence of different concentrations of TMZ, followed by an evaluation of IC50 for TMZ inhibited growth in A172-TR/A172, U118-TR/U118, U251-TR/U251 and U87-TR/U87

    Neurochem Res, 2016, 41(12):3192-3205. Temozolomide purchased from Selleck.

产品安全说明书

DNA/RNA Synthesis抑制剂选择性比较

生物活性

产品描述 Temozolomide(TMZ)是一种单功能的SN-1烷化剂,修饰DNA环上的氮原子以及环外氧基团。在生理pH值下,TMZ转化为活性产物MTIC、降解为methyldiazonium cation,后者再将甲基转移到DNA, 阻碍DNA复制启动,诱使细胞凋亡,是一种DNA损伤诱导剂。
特性 Methazolastone是第二代烷化剂。
靶点
DNA replication [1]
(L-1210, L-1210/BCNU cells)
体外研究

Methazolastone引起DNA碱不稳定位点的形成,其在L-1210和L-1210/BCNU细胞系中以相似数量存在,并且以相似比率修复。在L-1210中,methazolastone诱导细胞阻滞在SL-G2-M期,但在L-1210/BCNU中无此作用。[1]对化疗敏感与耐受的细胞(D54-R 和 U87-R)对Methazolastone的敏感性在高氧情况下被显著增强。Methazolastone和高氧均与ERK p44/42 MAPK (Erk1/2)磷酸化的增加相关,但是在D54-R细胞中增加程度较低,表明Erk1/2可能参与高氧与Methazolastone介导的细胞死亡的调节。高氧增强Methazolastone诱导细胞凋亡在GBM细胞中产生的细胞毒性,可能是通过MAPK相关的途径发挥作用。[2] Methazolastone诱导单核细胞中DNA损伤应答通路ATM-Chk2 和ATR-Chk1,导致p53活化。[3]长期Methazolastone暴露导致获得性Methazolastone耐药,并提高miR-21表达。[4] Methazolastone治疗引起内质网(ER)应激,增加GADD153和GRP78蛋白质表达,并减少caspase 12前体蛋白质。Methazolastone通过线粒体损伤和内质网应激依赖机制诱导自吞噬,以保护神经胶质瘤细胞。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NHPFPFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjLWFk1QCCq MmG5TWM2OD1zM{muNlDjiIoEsfMAjVUvQTVizszN MUOyOVk3ODJ6Mh?=
KellyCis83 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPBb2g1QCCq MnzkTWM2OD1{NUGuNFDjiIoEsfMAjVE2Njd3IN88US=> MkKzNlU6PjB{OEK=
SK-N-AS NVTC[I1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITBTWg1QCCq NUfFe4MxUUN3ME2yNlcvPzEkgJpCtgKBkTJ{LkG1JO69VQ>? NHfpSWwzPTl4MEK4Ni=>
SK-N-ASCis24 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV20PEBp NGfE[YlKSzVyPUS4NE43OOLCidMx5qCKOTBzLkG1JO69VQ>? NGHsPI4zPTl4MEK4Ni=>
CHP-212 M3TLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYO0PEBp NV2zPIJPUUN3ME23Mlk46oDLwsJihKkxNjZ7IN88US=> MXuyOVk3ODJ6Mh?=
CHP-212Cis100 M3Sx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGi1RpY1QCCq NHzXTFZKSzVyPUmuOVXjiIoEsfMAjVAvQDhizszN NUj3OHV5OjV7NkCyPFI>
U87  NYnUNYZjTnWwY4Tpc44hSXO|YYm= NX:4Smk3OTByIN88US=> NY\i[Xh6OjRvN{KgbC=> NE\sWo1qdmS3Y3XzJGRkWjFiZYjwdoV{e2mxbh?= MkXyNlU5ODh6Nki=
LN229 NXnHfpJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETm[I8xNTVyIN88US=> NEm2[2RKSzVyPUG2JO69VQ>? Mn33NlU4PTB{N{O=
TR-LN229 M1LiZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrMO3cxNTVyIN88US=> MnnkTWM2OD15NzFOwG0> MYeyOVc2ODJ5Mx?=
U87  NH\lXlBCeG:ydH;zbZMhSXO|YYm= M4\iPFDjiJN{MEFihKnDvU1? MWiyOEBp NX34SmlO\W6qYX7j[ZMhS1FiaX7keYNm\CCjcH;weI9{cXN? NYX6SopCOjV4OEG2Olg>
U251MG MVnBdI9xfG:|aYOgRZN{[Xl? M{PEb|ExOMLizszN MVW0PEBp NVvYWXpNWEKV MVfpcoR2[2W|IHHwc5B1d3Orcx?= Mn7JNlU3QDB2NkS=
U87MG M2nDVGFxd3C2b4Ppd{BCe3OjeR?= M37a[FExOMLizszN MX:0PEBp Ml31VGJU M4fSeYlv\HWlZYOgZZBweHSxc3nz NEfsTGczPTZ6MES2OC=>
U87 NWjSW4pnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jNPFUxNTN3MDFOwG0> NHnhNJU1QMLiaNMg NFW5[4FqdmirYnn0d{Bk\WyuIHfyc5d1cCC|bHnnbJRtgQ>? NHfzNJczPTV3NEKyNy=>
U118  MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TweFUxNTN3MDFOwG0> NYTOOGNSPDkEoHlCpC=> M2nDUYlvcGmkaYTzJINmdGxiZ4Lve5RpKHOuaXfoeIx6 MmXvNlU2PTR{MkO=
U87 MYTGeY5kfGmxbjDBd5NigQ>? NFP3emgzPTBxM{WwJO69VQ>? M2PDeFQ5yqCqwrC= M{PpSIVvcGGwY3XzJHROYC2rbnT1Z4VlKHBvUFvDMZBidiCmZXPy[YF{\Q>? NVLCUYtDOjV3NUSyNlM>
U118  M{fyNGZ2dmO2aX;uJGF{e2G7 Mk\FNlUxNzN3MDFOwG0> Mn\3OFjDqGkEoB?= NUjibYRK\W6qYX7j[ZMhXE2[LXnu[JVk\WRicD3QT2MueGGwIHTlZ5Jm[XOn MX6yOVU2PDJ{Mx?=
U87 M{DJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXuyOVAwOzVyIN88US=> NYjBOGhHPDkEoHlCpC=> NYLvb|c4cW6lcnXhd4V{KHSqZTDw[ZJk\W62YXflJI9nKGOnbHzzJIlvKFNiYX7kJGczN04EoHPveJJm[XSnZDD3bZRpKFSPWB?= MkjrNlU2PTR{MkO=
A375 MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XPU|Q5yqCqwrC= Mk\LTWM2OD1{NkWg{txO NF;P[4EzPTV{NEW1Ni=>
A2058 NV:yRpAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX76NIxMPDkEoHlCpC=> MnHBTWM2OD1zMjFOwG0> MoLaNlU2OjR3NUK=
M238 NIiyS|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHmTJVjPDkEoHlCpC=> NYrCfXRHUUN3ME20NEDPxE1? NH;LW3UzPTV{NEW1Ni=>
M249 M17rbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[0POKhcMLi M2nySmlEPTB;MkW0JO69VQ>? MlTyNlU2OjR3NUK=
M21 NEXBPXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnVXYhqPDkEoHlCpC=> MoG0TWM2OD1{MkGg{txO MUKyOVUzPDV3Mh?=
U251 Mof4R5l1d3SxeHn0fUBCe3OjeR?= MkKxNlAh|ryPwrC= M1jydVQ5yqCqwrC= NFrCc41z\WS3Y3Xkd{B1cGVicHXyZ4VvfGGpZYOgc4Yh[2:ub37p[ZMh\m:{bXXk NF\Oco4zPTR|NEO4NS=>
LN229 M1rFTGN6fG:2b4jpeJkhSXO|YYm= MmTGNlAh|ryPwrC= NVHJfWNJPDkEoHlCpC=> MnSydoVlfWOnZIOgeIhmKHCncnPlcpRi\2W|IH;mJINwdG:waXXzJIZwem2nZB?= M4XxXlI2PDN2M{ix
U373MG-LUC NUfm[VRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFyweXA4OiCq MUHJR|UxRjZyMDFOwG0> NUTBNm1yOjV2M{G5OVM>
U87  NH3WcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVWyOU0zODBizszN NX;tU4tIPDkEoHlCpC=> NF\lPXBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MU[yOVQxODd2NR?=
U251 M3X4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDRU|FWOjVvMkCwJO69VQ>? M{nnXVQ5yqCqwrC= MWDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NUDPb213OjV2MEC3OFU>
U251 M{XOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXnTYxYOTByLUSwNEDPxE1? NXfuOZpsPzJxOU[gbC=> MkW0eIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi MlfZNlU{PzV{N{G=
U373 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDMNVAxNTRyMDFOwG0> NVnKfHRnPzJxOU[gbC=> MoXFeIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi M{m2NFI2Ozd3Mkex
U343 NEfaSZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrIZocyODBvNECwJO69VQ>? NUnIOHpyPzJxOU[gbC=> NFnxUI51cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC= Mo\NNlU{PzV{N{G=
U87MG-luc2 Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HufFExOC12MECg{txO MYO3Nk86PiCq M{jCOJRp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= M{LPfFI2Ozd3Mkex
U87 M1:3UWZ2dmO2aX;uJGF{e2G7 NGmxS28zODBizszN Ml7OOFghcA>? NX71eVVIcW6lcnXhd4V{KEKUQ1OzJI1TVkFiZYjwdoV{e2mxbh?= MX[yOVM{Pzd{MR?=
U251 MUPGeY5kfGmxbjDBd5NigQ>? MoDmNlAxKM7:TR?= MknyOFghcA>? MWfpcoNz\WG|ZYOgRnJESzNibWLORUBmgHC{ZYPzbY9v NE\2S5IzPTN|N{eyNS=>
A172 NXz6TploTnWwY4Tpc44hSXO|YYm= NWTab3hQOjByIN88US=> Mn\0OFghcA>? MoT3bY5kemWjc3XzJGJTS0N|IH3SUmEh\XiycnXzd4lwdg>? MXeyOVM{Pzd{MR?=
U251 NIfrPZBHfW6ldHnvckBCe3OjeR?= NFz4SXYzODBizszN MYG0PEBp MlLkbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>? NWXLVnp7OjV|M{e3NlE>
A172 M1rlcGZ2dmO2aX;uJGF{e2G7 NVviU3B1OjByIN88US=> NYG0[VRXPDhiaB?= M2fuV4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBDWkODMTygRnJESTJuIGLBSFUyKGGwZDDGRW5ETDJ? NVvSUWJ2OjV|M{e3NlE>
U87 NWDkU|NLTnWwY4Tpc44hSXO|YYm= NFfTU4UzODBizszN MnjENlQwPzJxMUKwJIg> Moj3bY5kemWjc3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdiC2aX3lMYRmeGWwZHXueIx6 MnXoNlU{Ozd5MkG=
U251 MorUSpVv[3Srb36gRZN{[Xl? MW[yNFAh|ryP NUO2enc4OjRxN{KvNVIxKGh? MUHpcoNz\WG|ZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9vKHSrbXWt[IVx\W6mZX70cJk> NHrUR3UzPTN|N{eyNS=>
A172 NVHORXIyTnWwY4Tpc44hSXO|YYm= MniyNlAxKM7:TR?= NHLsT3MzPC95Mj:xNlAhcA>? MXjpcoNz\WG|ZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9vKHSrbXWt[IVx\W6mZX70cJk> MXeyOVM{Pzd{MR?=
SNB19V MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nEZ|ch\A>? NUL1fpJnTE2VTx?= MlHCS2k2OD1|NT63xtEyOiEQvF2= M{f3eFI2Ojd5NESx
SNB19M Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTic2t[PyCm MVrEUXNQ MnrXS2k2OD12NkmuPeKyQDhizszN MoXrNlUzPzd2NEG=
SNB19VR NE\TVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPRbo9TPyCm Mn7TSG1UVw>? MkWxS2k2OD1{OECuNuKyOThizszN NXzlUpVtOjV{N{e0OFE>
U373V NH3XdlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLrboRzPyCm NXTsb2tmTE2VTx?= M4K1eGdKPTB;NkiuNOKyOzJizszN MoHYNlUzPzd2NEG=
U373M NUHQSIFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHq[Gk4KGR? NWDwOoVGTE2VTx?= NIjse3NIUTVyPUO2PE44yrF6NjFOwG0> NYq4ZVJuOjV{N{e0OFE>
U373VR NUO0ZohzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[3S3hEPyCm NI\VO5RFVVOR MmDjS2k2OD1{OEiuPOKyOzNizszN MUOyOVI4PzR2MR?=
U87MG M{Syb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H6c|ch\A>? MorHSG1UVw>? NYW3dlY2T0l3ME2zPE4{yrF{MDFOwG0> MmrwNlUzPzd2NEG=
HCT116 NYjyVWptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYq3NYJmPyCm MlPpSG1UVw>? Mlj3S2k2OD13N{muPeKyOzJizszN NF3tUVkzPTJ5N{S0NS=>
DLD1 NHLmU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXaO{Bl M2TZdGROW09? M4TNbmdKPTB;NUCxMlTDuTl|IN88US=> MW[yOVI4PzR2MR?=
MRC5 MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LFPFch\A>? MUnEUXNQ MUjHTVUxRTR2OT60xtE5KM7:TR?= MnLGNlUzPzd2NEG=
SNB19V  NHXLOYhHfW6ldHnvckBCe3OjeR?= M2nnW|ExOCEQvF5CpHROYg>? M{nVd|AuPzJiaB?= MUTpcoNz\WG|ZYOg{tNJOkG[IHX4dJJme3Orb36gZoV1f2WnbjCxOkBidmRiN{KgbC=> MXKyOVI4PzR2MR?=
T98G  M1rwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnGxOU8yOC9zNTFOwG0> MofnNlTDqGh? MmH2bY5lfWOnczDj[YxtKGSnYYToJIRwe2VvZHXw[Y5l\W62bImgZYZ1\XJiY3;uZ49ucXSjboSteIVud3qxbH;tbYRmKHerdHigUnBmPi2SRGS= MoXENlUzPjJ7NkG=
U251  MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;l[4c3PS9zMD:xOUDPxE1? M4TNZlI1yqCq M3rZUIlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnLXTldIVv\GWwdHz5JIFnfGW{IHPvcoNwdWm2YX70MZRmdW:8b3zvcYll\SC5aYToJG5R\TZvUFTU MVyyOVI3Ojl4MR?=
T98G  NWHkRlhmTnWwY4Tpc44hSXO|YYm= MXmxOUDPxE1? MXmyOOKhcA>? NYiyOZZtcW6lcnXhd4V{KESQQT3mdoFodWWwdHH0bY9vKGmwIF7Q[VYuWESWIITy[YF1\WRiZ3zpc41iKGOnbHzz MWmyOVI3Ojl4MR?=
U251  NFjjXYFHfW6ldHnvckBCe3OjeR?= NIjrd40yPSEQvF2= Ml\MNlTDqGh? Ml7PbY5kemWjc3XzJGRPSS2ocnHncYVvfGG2aX;uJIlvKE6SZU[tVGRVKHS{ZXH0[YQh\2yrb33hJINmdGy| MUKyOVI3Ojl4MR?=
U-87 MG M3SzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fsOVczKGh? NXH5cJBLUUN3ME2wMlk{KG2PwrC= M3z3U|I2OjR3M{Oy
U-118 MG NUnzclczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fWW|czKGh? MnzHTWM2OD1zLkC1JI1OyqB? NW\1XlB7OjV{NEWzN|I>
U87 NFK0S4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[yOEBp MYnJR|UxRTJ4MD6zOEDPxE4EoB?= MUiyOVE4OzJ|Mx?=
U87 GSLCs NYrocWZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;nO5YzPCCq M3n2VWlEPTB;N{[2MlEyKM7:TdMg NYLDZlR4OjVzN{OyN|M>
U87MG NWTEXIZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL6O|IhcA>? NVP6c|F{UUN3ME2xOU43OjVizszNxsA> MWSyOVA2ODlzNR?=
U251 NInZZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;1NVAxNTRyMDFOwG0> NWixVXhTPDhiaB?= M1LoNmROW09? NWrVXYpxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYKyOFYzOzd|Nh?=
U87 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEi3d2gyODBvNECwJO69VQ>? Mln5OFghcA>? M4Hle2ROW09? MkmwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M37NNlI1PjJ|N{O2
MDA-MB-231-br MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYqwMVExKM7:TR?= NX:4RY1jPDhiaB?= NFrIPVVFVVOR MXPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NV7yVVl4OjR4MkO3N|Y>
HCC-1937 M2PLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jH[FAuOzByIN88US=> NVzsRWRCPDhiaB?= M1\GOmROW09? MkjqbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3LqXlI1PjJ|N{O2
MDA-MB-231 NH\Hc4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXOXVNwOC12MDFOwG0> NUjsWId6PDhiaB?= NF7hUGtFVVOR M1XHUolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2f1d|I1PjJ|N{O2
MDA-MB-468 NEi0RWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVewMVUxOCEQvF2= M{jKUVQ5KGh? M2OyV2ROW09? MkixbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWOyOFYzOzd|Nh?=
T47D M1fRXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWj2NY55OC1zMECg{txO NUDhWG9[PDhiaB?= NIXGclFFVVOR NUfDNFVycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFizbXMzPDZ{M{ezOi=>
MCF7 NXvWUmM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MViwMVExODBizszN NUTw[FNrPDhiaB?= NEXGd3NFVVOR MVzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NY[2bVdOOjR4MkO3N|Y>
Hs683 NEnsV3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPpVpkxNTFyMECg{txO M4P3S|k3KGh? M{PRT2lEPTB;MUK4Mlkh|ryP Mk\JNlQ1QTV7MEe=
U87 NXr5WlZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XBW|AuOTByMDFOwG0> MVi5OkBp M4W3V2lEPTB;MUiuOFUh|ryP M4[1OlI1PDl3OUC3
LNZ308 MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLVUpYxOC1zMECwJO69VQ>? M3XrXlk3KGh? MWHJR|UxRTN{Nj63JO69VQ>? MoPJNlQ1QTV7MEe=
U87 MYDBdI9xfG:|aYOgRZN{[Xl? NGLoNYYyODBizszN Mo\IOFghcA>? MkXUSG1UVw>? MlG4bY5kemWjc3XzJJRp\SClYYPwZZNmNTNxNzDhZ5Rqfmm2eR?= M1jDNlI1PDhzNUi2
U251  M2jBZmFxd3C2b4Ppd{BCe3OjeR?= MljJNVAxKM7:TR?= M3\nXlQ5KGh? NFnQNXJFVVOR NXTEeIZscW6lcnXhd4V{KHSqZTDjZZNx[XOnLUOvO{Bi[3Srdnn0fS=> MnjkNlQ1QDF3OE[=
U251 NYrqPVV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nXU|I1KGh? M3j0WWlEPTB;OE[uNlnjiIoEsfMAjVEvPThizszN MX2yOFMzPjl3NB?=
U251 M3LNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV60PEBp MnvWTWM2OD15NT6zOQKBkcLz4pEJNU4xOiEQvF2= M{\XW|I1OzJ4OUW0
U251 MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnRXGY4OiCq M1j4b2lEPTB;N{KuOFLjiIoEsfMAjVEvPDVizszN MViyOFMzPjl3NB?=
U251 NHjUUlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvSPVYhcA>? NHnWTXNKSzVyPU[5Mlgz6oDLwsJihKk{NjB2IN88US=> MW[yOFMzPjl3NB?=
T98G MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[wMVc2OCEQvF2= M3qyblczNzl4IHi= NIi5U2FqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MnTpNlQ{OjRyOEC=
U251-MG MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W1U|AuQDByIN88US=> M1PMZVczKGh? M{HTb4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M{nnS|I1ODl|NkOw
D54-MG NHjkOHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3tcIFOOC16MECg{txO MUS3NkBp NW\tOmhIcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= Ml7kNlQxQTN4M{C=
SHG-44 NF\ONGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVixNE0zODBizszN MUK5OkBp NHXCdHdKSzVyPUmuO|MhyrFiMj6xNkDPxE1? Moq0NlQxPjV3Nkm=
U373  NFX6SGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLjOJFSOTBvMkCwJO69VQ>? NE[5cWI6PiCq MU\JR|UxRTFyLkGzJOKyKDFwMEKg{txO NIjhdXQzPDB4NUW2PS=>
HT-29  MWTGeY5kfGmxbjDBd5NigQ>? NWLue25pPTByIN88US=> NHXHSZUzPC92ODDo MV\lcohidmOnczD0bIUhdGW4ZXzzJI9nKM7|LViyRXjDqA>? MXSyOFA{QDB4OB?=
PC-3  MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\GS21lOC1{NTFOwG0> M1HsN|Q5KGh? NYnFeWFtcW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJJBwfGWwdHnheIVlKGK7IHz5Z49x\W6n NFHHe4ozOzd2NkmzOC=>
PC-3  M3vtN2Fxd3C2b4Ppd{BCe3OjeR?= NG\lU4UzPSEQvF2= NITvVY01QCCq MWTpcoR2[2W|IHHwc5B1d3OrczD3bIlkcCClYX6gZoUheG:2ZX70bYF1\WRiYomgcJlkd3CnbnW= NGjRbXIzOzd2NkmzOC=>
T98G Mn3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LyZVUxNTRyMDFOwG0> Mk\TNVQ1KGh? MXrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MWKyN|cyPTR7OR?=
U87-MG M1[xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LJPVExOCEEtV2= MlrOO|IhcA>? MX\pcohq[mm2czDj[YxtKGe{b4f0bEB4cGmlaDDjZY4h[mViZX7oZY5k\WRiYomgS3RD NWnhXpg1OjN4OU[3PFg>
U251-MG M1rDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXuxNFAhyrWP M1[2cVczKGh? NV2yZXhFcW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KEeWQh?= NWX1fmNuOjN4OU[3PFg>
LNT-229 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXDWW0{NTFyMDFOwG0> MlvDNlQhcA>? NF3wXlBqdmirYnn0d{BkdG:wb3flcolkKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MorkNlM3Pjd4M{K=
T98G NG\LNmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fTUFExNTdyMDFOwG0> MkD3NlQhcA>? NXXNVpNUcW6qaXLpeJMh[2yxbn;n[Y5q[yC|dYL2bZZidCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MkfSNlM3Pjd4M{K=
U87  NYDa[JFWTnWwY4Tpc44hSXO|YYm= MoT6NVAxKML3TR?= NIDFcIQ{KGh? MU\lcIV3[XSnczD0bIUhdGW4ZXzzJI9nKHCFaHuxJIFv\CCyQ3jrNi=> NHTBTmEzOzZ4N{S2PS=>
HCT116 MnX5SpVv[3Srb36gRZN{[Xl? NV2xWIhUOTByINM1US=> NUf1enB4OyCq M4TZXIlv\HWlZYOgeIhmKEOqa{GgVIhwe3Cqb4L5cIF1cW:w NWj4SpM4OjN4Nke0Olk>
HCT3-6 MXjGeY5kfGmxbjDBd5NigQ>? M{jxd|ExOCEEtV2= MY[zJIg> MUfpcoR2[2W|IITo[UBEcGtzIGDoc5NxcG:{eXzheIlwdg>? NH7NW3ozOzZ4N{S2PS=>
U-87  Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[wMVQxKM7:TR?= M1rEU|EzKGR? NFPXSHJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NWDFPYo3OjN4NEW3Nlk>
U-87  M{fse2Fxd3C2b4Ppd{BCe3OjeR?= MlrxNE01OCEQvF2= MYizM|Yh\A>? MYDpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NFrqdZQzOzZ2NUeyPS=>
U-87  NXnmcGlGTnWwY4Tpc44hSXO|YYm= M2fYTVAuPDBizszN NF\mcHE{NzZiZB?= MVvpcoR2[2W|IHH1eI9xcGGpeTDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NUHHVIpDOjN4NEW3Nlk>
GB-SCC010 NV7PVll3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUi0JIQ> NFvHUJJKSzVyPUKyOkDPxE1? MXOyN|YyOjd3NR?=
GB-SCC026 MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jNPVQh\A>? M3PDeGlEPTB;NUOuNUDPxE1? M4rlPVI{PjF{N{W1
GB-SCC028 MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYeyXHB{PCCm NWTsVYVDUUN3ME2xOlch|ryP M33nN|I{PjF{N{W1
U87 NXHZeIF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjUeFA1KGR? MWjJR|UxRTR3LkKg{txO NIj5SmwzOzZzMke1OS=>
U87 stem cell MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fielQh\A>? Ml\6TWM2OD14Nj63JO69VQ>? MW[yN|YyOjd3NR?=

... Click to View More Cell Line Experimental Data

体内研究 每天腹腔注射40 mg/kg,连续5天(肿瘤移植后1-5天)后,在L-1210 和L-1210/BCNU中,methazolastone分别增加86%和22%的寿命。在L-1210/BCNU中,100 μM 或200 μM治疗后没有作用,仅400 μM methazolastone使细胞在有丝分裂前期产生积聚,但是在L-1210中效果较弱。在L-1210/BCNU中,SL-G2-M期细胞的最大积聚在48-72小时后,大约为30%,未处理的细胞为23%。患有L- 1210白血病的小鼠静脉注射methazolastone (40 mg/kg)时,也会使细胞在SL-G2-M期积聚。而给予相同剂量药物的小鼠L-1210/BCNU细胞中,没有此作用。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

+ 展开
  • Cell lines: L-1210 和 L-1210/BCNU 细胞
  • Concentrations: 0 μM -100 μM
  • Incubation Time: 1小时
  • Method:

    L-1210和L-1210/ BCNU细胞以0.2×104 cells/mL接种,并培养24小时。培养基用Methazolastone在37℃下处理1小时,然后用PBS洗涤两次,离心并重新悬浮在新鲜培养基中。对照组和处理试样在48小时时以1:4在新鲜培养基中稀释,第96小时时,以1:2稀释。整个实验中使用这些稀释的细胞浓度介于3×105和8×105/mL之间。该范围内对照组呈对数生长。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 负荷L-1210 和 L-1210/BCNU细胞的DBA/2小鼠
  • Formulation: 95%乙醇
  • Dosages: 40 mg/kg
  • Administration: 静脉注射给药
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+ddH2O
2mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 194.15
化学式

C6H6N6O2

CAS号 85622-93-1
稳定性 powder
in solvent
别名 CCRG81045, NSC 362856

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02977780 Recruiting Glioblastoma Dana-Farber Cancer Institute|Eli Lilly and Company|Celgene|Puma Biotechnology Inc.|Accelerate Brain Cancer Cure February 9 2017 Phase 2
NCT00392171 Completed Glioma|Astrocytoma|Oligodendroglioma|Glioblastoma Merck Sharp & Dohme Corp. June 9 2006 Phase 2
NCT00305864 Completed Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma National Cancer Institute (NCI)|Radiation Therapy Oncology Group February 9 2006 Phase 1|Phase 2
NCT00200161 Completed Glioblastoma|Gliomas Memorial Sloan Kettering Cancer Center|Schering-Plough|Columbia University|Dana-Farber Cancer Institute August 9 2005 Phase 2
NCT03528642 Not yet recruiting Anaplastic Astrocytoma IDH-Mutant|Diffuse Astrocytoma IDH-Mutant|IDH1 Gene Mutation|IDH2 Gene Mutation National Cancer Institute (NCI) February 8 2019 Phase 1
NCT03422445 Recruiting Advanced Melanoma Beijing Cancer Hospital January 8 2018 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

DNA/RNA Synthesis Signaling Pathway Map

相关DNA/RNA Synthesis产品

Tags: 购买Temozolomide | Temozolomide ic50 | Temozolomide价格 | Temozolomide DMSO溶解度 | 采购Temozolomide | Temozolomide生产 | Temozolomide 小鼠 | Temozolomide化学结构 | Temozolomide分子量 | Temozolomide molecular weight | Temozolomide说明书 | Temozolomide供应商 | Temozolomide体内 | Temozolomide细胞系 | Temozolomide浓度 | Temozolomide nmr | Temozolomide核磁 | Temozolomide半数抑制浓度 | Temozolomide体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID